Across TCGA pan-cancer cohorts, MAFB mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated MAFB data layer compared with 23 for mass-spec protein and 5 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MAFB mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MAFB expression acts as an unfavorable survival marker.
CCRCC are the cancer types where MAFB mass-spec protein most reproducibly stratifies survival.